Hungary's largest drugmaker Gedeon Richter (RICHT: HB) said today that it has launched its biosimilar teriparatide, brand name Terrosa, in Europe.
The product is approved in adults for the same indications as Eli Lilly’s (NYSE: LLY) reference product Forsteo, ie, used for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Forsteo generated global sales of $1.58 billion in 2018 for Lilly.
The product has been launched under the label Terrosa by Richter via its affiliates in Europe immediately following the patent expiry of the reference product in August 2019.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze